Overcoming on-target, off-tumour toxicity of CAR T cell therapy for solid tumours
Therapies with genetically modified T cells that express chimeric antigen receptors (CARs)
specific for CD19 or B cell maturation antigen (BCMA) are approved to treat certain B cell …
specific for CD19 or B cell maturation antigen (BCMA) are approved to treat certain B cell …
The evolution of synthetic receptor systems
Receptors enable cells to detect, process and respond to information about their
environments. Over the past two decades, synthetic biologists have repurposed physical …
environments. Over the past two decades, synthetic biologists have repurposed physical …
Immunogenicity of CAR-T cell therapeutics: evidence, mechanism and mitigation
Chimeric antigen receptor T cell (CAR-T) therapy demonstrated remarkable success in long-
term remission of cancers and other autoimmune diseases. Currently, six products (Kymriah …
term remission of cancers and other autoimmune diseases. Currently, six products (Kymriah …
Engineering programmable material-to-cell pathways via synthetic notch receptors to spatially control differentiation in multicellular constructs
Synthetic Notch (synNotch) receptors are genetically encoded, modular synthetic receptors
that enable mammalian cells to detect environmental signals and respond by activating user …
that enable mammalian cells to detect environmental signals and respond by activating user …
Control of the antitumour activity and specificity of CAR T cells via organic adapters covalently tethering the CAR to tumour cells
AV Stepanov, J **e, Q Zhu, Z Shen, W Su… - Nature Biomedical …, 2024 - nature.com
On-target off-tumour toxicity limits the anticancer applicability of chimaeric antigen receptor
(CAR) T cells. Here we show that the tumour-targeting specificity and activity of T cells with a …
(CAR) T cells. Here we show that the tumour-targeting specificity and activity of T cells with a …
Therapeutic cell engineering: designing programmable synthetic genetic circuits in mammalian cells
M Mansouri, M Fussenegger - Protein & Cell, 2022 - academic.oup.com
Cell therapy approaches that employ engineered mammalian cells for on-demand
production of therapeutic agents in the patient's body are moving beyond proof-of-concept in …
production of therapeutic agents in the patient's body are moving beyond proof-of-concept in …
Synnotch-programmed macrophages for cancerous cell detection and sensing
T Wang, CH Lau, N Wang, J Li, J Wang, Z Huang… - ACS …, 2024 - ACS Publications
Synthetic Notch (synNotch) receptors have enabled mammalian cells to sense extracellular
ligands and respond by activating user-prescribed transcriptional programs. Based on the …
ligands and respond by activating user-prescribed transcriptional programs. Based on the …
Universal CAR 2.0 to overcome current limitations in CAR therapy
LS Schlegel, C Werbrouck, M Boettcher… - Frontiers in …, 2024 - frontiersin.org
Chimeric antigen receptor (CAR) T cell therapy has effectively complemented the treatment
of advanced relapsed and refractory hematological cancers. The remarkable achievements …
of advanced relapsed and refractory hematological cancers. The remarkable achievements …
ReCARving the future: bridging CAR T-cell therapy gaps with synthetic biology, engineering, and economic insights
A Ali, JF DiPersio - Frontiers in immunology, 2024 - frontiersin.org
Chimeric antigen receptor (CAR) T-cell therapy has revolutionized the treatment of
hematologic malignancies, offering remarkable remission rates in otherwise refractory …
hematologic malignancies, offering remarkable remission rates in otherwise refractory …
Tuning CARs: recent advances in modulating chimeric antigen receptor (CAR) T cell activity for improved safety, efficacy, and flexibility
Cancer immunotherapies utilizing genetically engineered T cells have emerged as powerful
personalized therapeutic agents showing dramatic preclinical and clinical results …
personalized therapeutic agents showing dramatic preclinical and clinical results …